Final Pharm Test 2

Front 1

Hormones and Antagonists

Back 1

Least toxic don't harm DNA

Front 2

Used for cancers arising from lymphoid tissue. Management of N/V ect.

Back 2

Glucocorticoids (Prednisone)

Front 3

Selective estrogen receptor modulator (SERM)
Blocks some, activates others
Blockade - Breast Cancer
Activation - increased risk for endometrial cancer*

Back 3

Tamoxifen (Nolvadex)

Front 4

Pure estrogen receptor antagonist.
Relatively new breast cancer treatment

Back 4

Fulvestrant (Faslodex)

Front 5

Aromatase Inhibitor
Block estrogen production. Does not block production by the ovaries.
Well tolerated compared to Tamoxifen.
No risk of endometrial cancer

Back 5

Anastrozole (Arimidex)

Front 6

Aromatase Inhibitor
AEs include musculoskeletal pain and nausea

Back 6

Letrozole (Femara)

Front 7

Well tolerated Aromatase Inhibitor

Back 7

Exemestane (Aromasin)

Front 8

Palliative therapy for advanced breast cancer.
Virilization common.
Oral (liver tox) Patch ect.

Back 8

Androgens: Testosterone, Testolactone (Teslac) and Fluoxymesterone (Halotestin)

Front 9

Progestin (Endometrial cancer, palliation, and tumor regression. Vital time increased to about 2 years

Back 9

Medroxyprogesterone acetate (Depo Provera) or megestrol acetate (Megace)

Front 10

GnRH agonist suppresses androgens from testes.
Indirect anti-androgen
Leads to desensitization*
For advanced carcinoma (PROSTATE CANCER), alternative to castration
Trasient increased flare block with flutamide

Back 10

Leuprolide (Lupron)

Front 11

Used in combination only to block receptors from adrenal release to block transiant flare of androgens

Back 11

Flutamide (Eulexin)

Front 12

An estrogen couple to an alkylating agent which takes it to an adrogen receptor.
Pallitive therapy of advanced prostate cancer.

Back 12

Estramustine (Emcyt)

Front 13

GnRH antagonist, blocks receptors in the pituitary
No "Flare" but can diminish with time.
4% = severe, immediate onset, allergic reactions

Back 13

Abarelix (Plenaxis)

Front 14

Immuno-stimulant
Enhance host response and decrease cancer growth. antiproliferative

Back 14

Interferon alfa-2a and Interferon alfa-2b

Front 15

Immuno-stim. Sig. Toxicity, Fatality rate = 4%, only used for aggresive matastic cancers

Back 15

Aldesleukin (IL-2)

Front 16

Restores depressed immune responses, no effect on normal responses, used in combination therapy. MOA unknown.

Back 16

Levamisole (Eramisol)

Front 17

Used in bladder cancers. Mycobacterium bovis, non-specific immunostimulant with a live bacillus. Unusual route hold no diuresis.

Back 17

BCG vaccine (theracys, TICE, BCG, Pacis)

Front 18

Hematopoietic growth factor, Recombinant DNA technology.
Used with anemia of chronic renal failure, HIV infected patients taking zidovudine
Chemotherapy induced anemia
Anemia in patients facing surgery
AEs
HTN, Autoimmune pure red cell aplasia rarely, CV events r/t HTN
Don't use with leukemia

Back 18

Epoetin alfa (Epogen, Procrit)

Front 19

Angiogenesis Inhibitor first approved MAB against VGEF binds to it

Back 19

Bevacizumab (Avastin)

Front 20

BCR_ABL tyrosine kinase inhibitor
Model of succesful targeted anti-cancer drug.
Philadelphia Chromosome
Chronic Myeloid Leukemia
Oral delivery, highly effective and well tolerated

Back 20

Imatinib (Gleevac)

Front 21

EGFR-tyrosine kinase inhibitor
Competative EGFR antagonist - apoptosis, blocks growth slow IV infusion, AEs in most patients N/V ect. EGFR positive colorectal cancer
Blocks receptor

Back 21

Cetuximab (Erbitux)